IRadimed Statistics
Total Valuation
IRadimed has a market cap or net worth of $572.42 million. The enterprise value is $529.23 million.
| Market Cap | 572.42M |
| Enterprise Value | 529.23M |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, before market open.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | May 17, 2024 |
Share Statistics
IRadimed has 12.66 million shares outstanding. The number of shares has increased by 0.50% in one year.
| Shares Outstanding | 12.66M |
| Shares Change (YoY) | +0.50% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 37.04% |
| Owned by Institutions (%) | 54.70% |
| Float | 7.16M |
Valuation Ratios
The trailing PE ratio is 32.06 and the forward PE ratio is 37.55. IRadimed's PEG ratio is 4.46.
| PE Ratio | 32.06 |
| Forward PE | 37.55 |
| PS Ratio | 8.46 |
| Forward PS | 10.20 |
| PB Ratio | 7.52 |
| P/FCF Ratio | 53.13 |
| PEG Ratio | 4.46 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.58, with an EV/FCF ratio of 49.13.
| EV / Earnings | 29.53 |
| EV / Sales | 7.82 |
| EV / EBITDA | 22.58 |
| EV / EBIT | 23.38 |
| EV / FCF | 49.13 |
Financial Position
The company has a current ratio of 9.44, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.44 |
| Quick Ratio | 7.64 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.18 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 24.60% and return on invested capital (ROIC) is 21.08%.
| Return on Equity (ROE) | 24.60% |
| Return on Assets (ROA) | 20.50% |
| Return on Capital (ROIC) | 21.08% |
| Revenue Per Employee | $457,333 |
| Profits Per Employee | $121,103 |
| Employee Count | 148 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.67 |
Taxes
In the past 12 months, IRadimed has paid $4.71 million in taxes.
| Income Tax | 4.71M |
| Effective Tax Rate | 20.81% |
Stock Price Statistics
The stock price has decreased by -2.61% in the last 52 weeks. The beta is 0.84, so IRadimed's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -2.61% |
| 50-Day Moving Average | 43.49 |
| 200-Day Moving Average | 43.04 |
| Relative Strength Index (RSI) | 55.19 |
| Average Volume (20 Days) | 52,604 |
Short Selling Information
The latest short interest is 143,181, so 1.13% of the outstanding shares have been sold short.
| Short Interest | 143,181 |
| Short Previous Month | 133,979 |
| Short % of Shares Out | 1.13% |
| Short % of Float | 2.00% |
| Short Ratio (days to cover) | 2.78 |
Income Statement
In the last 12 months, IRadimed had revenue of $67.69 million and earned $17.92 million in profits. Earnings per share was $1.41.
| Revenue | 67.69M |
| Gross Profit | 51.82M |
| Operating Income | 20.78M |
| Pretax Income | 22.63M |
| Net Income | 17.92M |
| EBITDA | 23.44M |
| EBIT | 22.63M |
| Earnings Per Share (EPS) | $1.41 |
Balance Sheet
The company has $45.13 million in cash and $1.94 million in debt, giving a net cash position of $43.19 million or $3.41 per share.
| Cash & Cash Equivalents | 45.13M |
| Total Debt | 1.94M |
| Net Cash | 43.19M |
| Net Cash Per Share | $3.41 |
| Equity (Book Value) | 76.12M |
| Book Value Per Share | 6.01 |
| Working Capital | 64.27M |
Cash Flow
In the last 12 months, operating cash flow was $12.70 million and capital expenditures -$1.93 million, giving a free cash flow of $10.77 million.
| Operating Cash Flow | 12.70M |
| Capital Expenditures | -1.93M |
| Free Cash Flow | 10.77M |
| FCF Per Share | $0.85 |
Margins
Gross margin is 76.57%, with operating and profit margins of 30.70% and 26.48%.
| Gross Margin | 76.57% |
| Operating Margin | 30.70% |
| Pretax Margin | 33.44% |
| Profit Margin | 26.48% |
| EBITDA Margin | 34.63% |
| EBIT Margin | 33.44% |
| FCF Margin | 15.92% |
Dividends & Yields
This stock pays an annual dividend of $0.15, which amounts to a dividend yield of 0.33%.
| Dividend Per Share | $0.15 |
| Dividend Yield | 0.33% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.64% |
| Buyback Yield | -0.50% |
| Shareholder Yield | -0.17% |
| Earnings Yield | 3.13% |
| FCF Yield | 1.88% |
Analyst Forecast
The average price target for IRadimed is $65.00, which is 43.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $65.00 |
| Price Target Difference | 43.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IRadimed has an Altman Z-Score of 32.13 and a Piotroski F-Score of 6.
| Altman Z-Score | 32.13 |
| Piotroski F-Score | 6 |